Get App
Indian pharma companies are expected to continue their growth momentum and profitability in US, helped by new product launches, ongoing drug shortages and growth opportunities in the domestic formulation business, according to rating agency India Ratings and Research (Ind-Ra). The ...
Concord Biotech Ltd initial public offering (IPO) opens for subscription on August 4 (Friday) and closes on August 8, 2023 (Tuesday). The price band is set at Rs 705—741 per share. The company’s employees will get a discount of Rs ...
Mankind Pharma plans to raise up to Rs 4326.36 crore through initial public offering (IPO). The IPO subscription will open on April 25 and close on April 27. The price band is fixed at Rs 1026 – Rs 1080 apiece.The ...
The domestic active pharmaceutical ingredient (API) industry is expected to grow at a CAGR of about 7%-8% over the next three to four years, according to ICRA rating agency. The estimated size of the industry is about Rs. 1,000-1,100 billion ...
India Ratings and Research (Ind-Ra) said that it expects the US drug regulator’s inspection in 2023 and 2024 to be less disruptive for the sector and will only have an impact on some facilities and entities compared to the situation ...
The Indian pharmaceutical sector is expected to see a moderate revenue growth of 9% in fiscal year 2022, compared with a revenue growth of 12.5% in the last financial year, due to sluggishness in exports, according to Crisil Rating agency. ...